Hemoptysis (>  teaspoon [. mL] of bright red blood) within  months prior to randomization
Severe, active co-morbidity defined as follows:\r\n* Current (within  days of cycle , day ) signs and/or symptoms of bowel obstruction\r\n* Patients who require parental hydration and/or nutrition\r\n* Patients who require drainage gastrostomy tube\r\n* Evidence of bleeding diathesis or clinically significant coagulopathy\r\n* Serious, non-healing or dehiscing wound, active ulcer or untreated bone fracture\r\n* History of hemoptysis (>= / teaspoon of bright red blood per episode) within  month of study enrollment
History of hemorrhage or hemoptysis (>  teaspoon bright red blood) within  months of starting study treatment
Active hemoptysis (bright red blood of at least . teaspoon) within  weeks prior to the first dose of study drug
Pulmonary hemorrhage or gross hemoptysis (bright red blood of >= / teaspoon per episode) within  months prior to enrollment
History of hemoptysis (>= / teaspoon of bright red blood per episode) within  month prior to day 
Patients with history of hematemesis or hemoptysis (defined as having bright red blood of / teaspoon or more per episode) within  days prior to registration
History of pulmonary hemorrhage/hemoptysis >= grade  (defined as >= . mL bright red blood per episode) within  month prior to randomization.
History of hemorrhage or hemoptysis (>  teaspoon bright red blood) within  months prior to study treatment
(Bevacizumab-related exclusion) History of hemoptysis (>= / teaspoon of bright red blood per episode) within  month of study enrollment for any tumor type
History of hemoptysis (>= / teaspoon of bright red blood per episode) within  month of study enrollment
History of hemoptysis (>= / teaspoon of bright red blood per episode) =<  days of study enrollment
History of hemoptysis (defined as > / tablespoon [tsp] of bright red blood per day)
Patients with hemoptysis (defined as bright red blood or >= / teaspoon) within  months prior to enrollment, or with central or cavitating lesions, will be excluded
History of pulmonary hemorrhage/hemoptysis >= grade  (defined as >= . mL bright red blood per episode) within  month prior to on-study date
Gastrointestinal bleeding or active hemoptysis (bright red blood of at least half teaspoon) within  weeks prior to the first dose of study drug.
History of hemorrhage or hemoptysis (> / teaspoon bright red blood) within  months of starting study treatment
History of hemoptysis ( >= / teaspoon of bright red blood per episode) within  month prior to day 
History of hemoptysis (>= / teaspoon of bright red blood per episode) within  month prior to day  of FOLFIRI + bevacizumab initiation
Active hemoptysis (bright red blood of at least . teaspoon) or tumor bleeding within  weeks prior to the first dose of study drug
History of hemoptysis (? / teaspoon of bright red blood per episode) within  month prior to Day 
Bleeding diathesis including clinically significant platelet disorders or active hemoptysis (defined as bright red blood of ? / teaspoon [. mL] in any  hour period) within  months prior to study day . For clinically significant epistaxis within  weeks prior to study day , no risk of further bleeding must be clearly documented.
History of hemorrhage or hemoptysis (>  teaspoon bright red blood) within  months of starting study treatment
No active or recent hemoptysis (>= / teaspoon of bright red blood per episode) =<  days prior to registration
Patients are excluded if they have a history of hemoptysis (bright red blood of / teaspoon or more per episode) within  months prior to randomization
History of hemorrhage or hemoptysis (>  teaspoon bright red blood) within  months of starting study treatment
History of hemoptysis (>= / teaspoon of bright red blood per episode) within  month of study enrollment for any tumor type
Active hemoptysis (bright red blood of at least . mL ie, half teaspoon) within  weeks prior to the first dose of study drug.
History of hemoptysis (>= / teaspoon of bright red blood per episode) or other significant spontaneous bleeding event within  month prior to day  of study drug or at any time on a prior VEGF inhibitor
Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least . teaspoon) within  days prior to randomization
Have a significant bleeding disorder or vasculitis or had a Grade ? bleeding episode within  weeks prior to enrollment. Participants with a history of gross hemoptysis (defined as bright red blood of ?/ teaspoon) within  months prior to enrollment are excluded.
Active or recent history of hemoptysis (>= / teaspoon of bright red blood per episode) =<  days prior to registration/randomization
Gastrointestinal bleeding or active hemoptysis (bright red blood of at least half teaspoon) within  days prior to enrollment
Active hemoptysis (bright red blood of at least . teaspoon) within  weeks before the first dose of study drug.
History of hemoptysis (/ teaspoon of bright red blood per episode) within  month prior to Day .
No history of gross hemoptysis (defined as bright red blood of a half-teaspoon or more) within  months prior to enrollment
History of hemoptysis >= grade  (defined as bright red blood of at least . mL) =<  months prior to randomization
History of gastrointestinal (GI) bleeding (hemoptysis/melena/hematochezia, >= / teaspoon of bright red blood per episode) within  month prior to day 
History of hemoptysis (>= / teaspoon of bright red blood per episode) within  month prior to day -
History of hemoptysis (>= / teaspoon of bright red blood per episode) within  month prior to day 
History of uncontrolled hemoptysis (>= / teaspoon of bright red blood per episode) within  month prior to day 
History of hemoptysis (greater than or equal to / teaspoon of bright red blood per episode) within  month prior to day 
History of hemoptysis ( >= / teaspoon of bright red blood per episode) within  month prior to Day 
History of hemoptysis (>/=/ teaspoon of bright red blood per episode) within  month prior to Day .
History of/or current evidence of hemoptysis (bright red blood of  teaspoon or more)
History of hemoptysis (? / teaspoon of bright red blood per episode) within  month prior to Day 
Patients with a history of gross hemoptysis (defined as bright red blood of  teaspoon or more) will be excluded from this trial
History of hemoptysis (>= / teaspoon of bright red blood per episode) within  month prior to Day 
History of hemoptysis (>=  teaspoon of bright red blood per episode) within  month prior to day 
History of hemoptysis (>= / teaspoon of bright red blood per episode) within  month prior to day 
Active hemoptysis (bright red blood >  teaspoon on more than one occasion) =<  weeks prior to registration
Active hemoptysis (bright red blood of at least . teaspoon) within  weeks prior to the first dose of study drug.
